Dilip Bhat, Joint MD of Prabhudas Lilladher told CNBC-TV18, "Ranbaxy Laboratories is one of the few stocks where the past is coming back to haunt them. I believe it is very needless because all those things are very much in the public domain but may be the way the articles and the news press items appear, they appear very daunting. So the past is behind us."
He further added, "What we need to see is that is the future really going to unfold, are the margins going to go up? This is what we are thinking that overall operating margins, core margins will continue to go northwards."
"This is a stock which one can still bet on. There can be some bad news once again about the past which could rear its head again, but if you look a little more forward, I think Ranbaxy still looks reasonably available at the current levels. It is a good investment bet," he said.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
